Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
60 shown of 5,932 total abstracts
  1. Abstract 94722026-06-05 · 15:00 CT · S406
    PACIFIC-469: Imfinzi (durvalumab) 3L+ in SCLC
    E. Winer, M. Krop, P. Schmid, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  2. Abstract 93292026-06-03 · 20:45 CT · S100A
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-59
    S. Tolaney, S. Antonia, E. Winer · Massachusetts General Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  3. Abstract 92912026-06-04 · 15:45 CT · E450
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    M. Reck, J. Cortes, P. Schmid · Cleveland Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  4. Abstract 97342026-06-05 · 21:15 CT · S100A
    FLAURA-978: Tagrisso (osimertinib) neoadjuvant in NSCLC
    R. Herbst, T. Mok, F. Andre, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  5. Abstract 96232026-06-04 · 19:00 CT · S100A
    KEYNOTE-584: Keytruda (pembrolizumab) maintenance in NSCLC
    H. Rugo, A. Spira, S. Peters, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  6. Abstract 96512026-06-03 · 19:30 CT · S100A
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-744
    F. Andre, C. Robert, S. Modi, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  7. Abstract 96022026-06-05 · 15:00 CT · Hall B1
    PACIFIC-368: Imfinzi (durvalumab) 3L+ in SCLC
    J. Cortes, N. Rizvi · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  8. Abstract 98542026-06-05 · 20:15 CT · E450
    Long-term follow-up of Enhertu neoadjuvant for NSCLC: DESTINY-Breast-668
    A. Spira, F. Andre, H. Rugo, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  9. Abstract 90462026-06-02 · 18:00 CT · S100A
    Long-term follow-up of Imfinzi 3L+ for NSCLC: PACIFIC-835
    E. Winer, S. Antonia, P. Schmid, et al. · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  10. Abstract 98552026-06-05 · 13:15 CT · S406
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    C. Saura, S. Antonia, H. Rugo, et al. · University of Chicago
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  11. Abstract 90572026-06-03 · 15:30 CT · E450
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-590
    C. Saura, M.C. Garassino, M. Krop, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  12. Abstract 98322026-06-05 · 20:00 CT · Arie Crown Theater
    Long-term follow-up of Imfinzi 2L for NSCLC: PACIFIC-949
    A. Spira, R. Herbst · Stanford Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  13. Abstract 94372026-06-02 · 21:00 CT · Hall B1
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-29
    H. Rugo, A. Spira, M. Reck, et al. · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  14. Abstract 98072026-06-03 · 13:45 CT · S100A
    FLAURA-571: Tagrisso (osimertinib) 1L in NSCLC
    M.C. Garassino, H. Borghaei, T. Mok · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  15. Abstract 96262026-06-02 · 14:45 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-948
    A. Spira, S. Modi, T. Mok · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  16. Abstract 94482026-06-02 · 21:30 CT · Arie Crown Theater
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    M. Krop, F. Andre · Karolinska Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  17. Abstract 93432026-06-02 · 13:45 CT · S100A
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-398 study)
    H. Borghaei, N. Rizvi, S. Modi, et al. · University of Chicago
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  18. Abstract 93602026-06-01 · 21:00 CT · S406
    Long-term follow-up of Opdivo adjuvant for NSCLC: CheckMate-346
    R. Herbst, E. Winer, P. Schmid · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  19. Abstract 99082026-06-03 · 21:15 CT · Hall B1
    Long-term follow-up of Keytruda adjuvant for SCLC: KEYNOTE-521
    C. Robert, S. Modi, H. Borghaei, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  20. Abstract 92862026-06-03 · 21:30 CT · Hall B1
    IMpower-739: Tecentriq (atezolizumab) 3L+ in NSCLC
    S. Peters, H. Borghaei, P. Schmid · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  21. Abstract 90312026-06-02 · 21:45 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-152 study)
    H. Borghaei, S. Tolaney, N. Rizvi · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  22. Abstract 92642026-06-04 · 20:45 CT · Arie Crown Theater
    PACIFIC-222: Imfinzi (durvalumab) neoadjuvant in SCLC
    F. Andre, P. Schmid · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  23. Abstract 97502026-06-01 · 16:00 CT · E450
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-786
    S. Antonia, E. Winer, J. Brahmer, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  24. Abstract 90942026-06-04 · 15:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-338 study)
    S. Antonia, L. Paz-Ares · Mayo Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  25. Abstract 95432026-06-04 · 18:30 CT · Arie Crown Theater
    PACIFIC-537: Imfinzi (durvalumab) 2L in SCLC
    S. Modi, C. Saura, J. Brahmer · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  26. Abstract 95132026-06-02 · 16:30 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with NSCLC
    S. Modi, M. Krop, M.C. Garassino, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  27. Abstract 91032026-06-01 · 20:45 CT · S406
    Long-term follow-up of Imfinzi neoadjuvant for NSCLC: PACIFIC-959
    S. Tolaney, P. Schmid, J. Cortes · Massachusetts General Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  28. Abstract 99312026-06-02 · 16:30 CT · S406
    Long-term follow-up of Opdivo neoadjuvant for NSCLC: CheckMate-149
    S. Modi, J. Brahmer, C. Robert · Massachusetts General Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  29. Abstract 96392026-06-04 · 13:30 CT · S100A
    Long-term follow-up of Opdivo 2L for NSCLC: CheckMate-794
    T. Mok, G. Curigliano · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  30. Abstract 97782026-06-02 · 19:00 CT · S100A
    Long-term follow-up of Imfinzi 3L+ for SCLC: PACIFIC-833
    C. Robert, L. Paz-Ares, S. Tolaney · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  31. Abstract 95882026-06-02 · 13:30 CT · Arie Crown Theater
    Long-term follow-up of Tecentriq 1L for NSCLC: IMpower-428
    S. Peters, A. Spira, L. Paz-Ares · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  32. Abstract 93612026-06-03 · 16:00 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-379
    A. Spira, J. Cortes, S. Antonia · University of Chicago
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  33. Abstract 97522026-06-04 · 18:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-982 study)
    T. Mok, J. Cortes · University of Chicago
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  34. Abstract 92552026-06-01 · 13:15 CT · E450
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-875
    R. Herbst, T. Mok, G. Curigliano, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  35. Abstract 90072026-06-04 · 13:15 CT · S100A
    Quality of life outcomes with Tagrisso in patients with NSCLC
    C. Robert, S. Peters, L. Paz-Ares, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  36. Abstract 99862026-06-04 · 21:45 CT · Hall B1
    Quality of life outcomes with Imfinzi in patients with SCLC
    S. Tolaney, C. Saura, F. Andre · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  37. Abstract 92152026-06-05 · 19:30 CT · Arie Crown Theater
    CheckMate-893: Opdivo (nivolumab) 3L+ in NSCLC
    F. Andre, P. Schmid, S. Tolaney, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  38. Abstract 94842026-06-01 · 20:45 CT · Hall B1
    FLAURA-895: Tagrisso (osimertinib) 2L in NSCLC
    T. Mok, L. Paz-Ares, J. Brahmer, et al. · University of Chicago
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  39. Abstract 98602026-06-05 · 19:15 CT · Hall B1
    IMpower-804: Tecentriq (atezolizumab) adjuvant in NSCLC
    R. Herbst, T. Mok, H. Borghaei · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  40. Abstract 95512026-06-03 · 13:15 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-104 study)
    P. Schmid, A. Spira, M.C. Garassino, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  41. Abstract 93662026-06-02 · 16:15 CT · S100A
    Long-term follow-up of Keytruda maintenance for SCLC: KEYNOTE-227
    R. Herbst, M. Reck · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  42. Abstract 94972026-06-03 · 14:45 CT · Hall B1
    PACIFIC-955: Imfinzi (durvalumab) adjuvant in NSCLC
    P. Schmid, S. Tolaney, S. Peters, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  43. Abstract 92262026-06-04 · 16:30 CT · S100A
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    N. Rizvi, P. Schmid, M. Krop, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  44. Abstract 93672026-06-04 · 21:15 CT · Arie Crown Theater
    PACIFIC-371: Imfinzi (durvalumab) 3L+ in SCLC
    M. Reck, J. Cortes · Cleveland Clinic
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  45. Abstract 98472026-06-05 · 21:15 CT · S100A
    Long-term follow-up of Imfinzi neoadjuvant for SCLC: PACIFIC-591
    M.C. Garassino, S. Modi, J. Brahmer · Stanford Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  46. Abstract 94632026-06-02 · 20:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-86 study)
    S. Antonia, A. Spira, J. Cortes, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  47. Abstract 90902026-06-02 · 14:15 CT · S406
    Quality of life outcomes with Enhertu in patients with NSCLC
    M. Reck, R. Herbst, T. Mok · Stanford Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  48. Abstract 93712026-06-05 · 19:30 CT · S406
    IMpower-530: Tecentriq (atezolizumab) 3L+ in NSCLC
    S. Modi, S. Tolaney, J. Brahmer, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  49. Abstract 96082026-06-03 · 13:00 CT · Arie Crown Theater
    KEYNOTE-69: Keytruda (pembrolizumab) 3L+ in NSCLC
    R. Herbst, N. Rizvi, H. Rugo, et al. · Mayo Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  50. Abstract 97442026-06-01 · 20:30 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-88 study)
    C. Saura, C. Robert · Mayo Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  51. Abstract 94932026-06-05 · 18:00 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-417 study)
    M.C. Garassino, C. Saura, L. Paz-Ares, et al. · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  52. Abstract 98492026-06-04 · 16:00 CT · S100A
    DESTINY-Breast-892: Enhertu (trastuzumab deruxtecan) maintenance in NSCLC
    P. Schmid, H. Borghaei, N. Rizvi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  53. Abstract 91822026-06-05 · 18:15 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-891
    N. Rizvi, G. Curigliano, S. Antonia, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  54. Abstract 96502026-06-01 · 14:15 CT · S406
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-181 study)
    S. Antonia, T. Mok · Massachusetts General Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  55. Abstract 97232026-06-02 · 15:00 CT · E450
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-792 study)
    S. Tolaney, H. Rugo · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  56. Abstract 96082026-06-01 · 15:15 CT · S100A
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-665 study)
    L. Paz-Ares, T. Mok, C. Saura, et al. · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  57. Abstract 92392026-06-04 · 19:45 CT · S406
    FLAURA-363: Tagrisso (osimertinib) maintenance in NSCLC
    E. Winer, C. Saura, M. Reck, et al. · University of Chicago
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  58. Abstract 92752026-06-05 · 20:00 CT · Hall B1
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    S. Modi, H. Borghaei, N. Rizvi, et al. · Karolinska Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  59. Abstract 95512026-06-04 · 14:00 CT · S406
    FLAURA-213: Tagrisso (osimertinib) 1L in NSCLC
    S. Peters, R. Herbst · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  60. Abstract 92372026-06-04 · 18:00 CT · S100A
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-683
    S. Peters, P. Schmid, J. Cortes, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.